MicroRNA-431 serves as a tumor inhibitor in breast cancer through targeting FGF9

12Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Breast cancer has become an important public health problem. Moreover, the functions of microRNA-431 (miR-431) have been detected in human cancers other than breast cancer. Hence, we investigated the role of miR-431 in progression of breast cancer. RT-qPCR and Western blot analysis were performed to assess expression of miR-431 and genes. The regulatory mechanism of miR-431 was investigated using MTT, Transwell and luciferase reporter assay. Decreased miR-431 expression was identified in breast cancer, which was related to aggressive behavior. Furthermore, miR-431 restrained cell proliferation, metastasis and EMT in breast cancer. miR-431 induced apoptosis through enhancing Bax expression. In addition, miR-431 was found to directly target FGF9. Moreover, upregulation of FGF9 impaired the anti-tumor effect of miR-431 in breast cancer. miR-431 restrained cell viability and metastasis in breast cancer through targeting FGF9, indicating that miR-431 serves as a tumor inhibitor in breast cancer.

Cite

CITATION STYLE

APA

Wang, W., Dong, Y., Li, X., Pan, Y., Du, J., & Liu, D. (2020). MicroRNA-431 serves as a tumor inhibitor in breast cancer through targeting FGF9. Oncology Letters, 19(1), 1001–1007. https://doi.org/10.3892/ol.2019.11126

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free